Barclays
ATRA icon

Barclays’s Atara Biotherapeutics ATRA Stock Holding History

Barclays’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,480
Closed -$2.28M – 7099
2018
Q2 		$2.28M Buy
+2,480
New +$2.66M ﹤0.01% 2462
2017
Q3 		– Sell
-1,400
Closed -$490K – 6833
2017
Q2 		$490K Buy
+1,400
New +$539K ﹤0.01% 3551

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's ATRA Position: Q2 2026 in Review

Barclays opened a new position in Atara Biotherapeutics (ATRA) in Q2 2026: 304 shares worth $3.49K. The stake represents ﹤0.01% of the portfolio and ranks #4813 among its holdings. This is a return to the name: Barclays previously reported a position in ATRA as recently as Q1 2025.

Barclays first reported a position in ATRA in Q4 2014 and has held it in 40 quarters since. The position peaked at $5.43M in Q3 2021. 36 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Barclays held 304 shares of Atara Biotherapeutics worth $3.49K as of Q2 2026.
  • Atara Biotherapeutics was a new Barclays position in Q2 2026.
  • Atara Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4813 holding.
  • Barclays first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 40 quarters since.
  • Barclays's Atara Biotherapeutics position peaked at $5.43M in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.